Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

Abstract	Granulocyte colony-stimulating factors (G-CSFs) reduce febrile neutropaenia (FN) incidence but may be used inconsistently in current practice (CP). This study compared the efficacy of pegfilgrastim primary prophylaxis (PPP) with CP neutropaenia management in breast cancer. Individual patient data (N=2282) from 11 clinical trials and observational studies using chemotherapy regimens with > or =15% FN risk and PPP (6 mg, all cycles) or CP (no G-CSF or any cycle G-CSF/pegfilgrastim) were included in an integrated analysis. Most patients received docetaxel-containing regimens. A generalised linear mixed model was fitted (N=2210). Neutropaenia prophylaxis (PPP versus CP), age and disease stage influenced the incidence of FN. Overall, FN was less frequent with PPP than with CP (odds ratio [OR]: 0.124; 95% confidence interval [CI]: 0.08, 0.194; P<0.0001). Odds for cycle 1 FN, dose reductions > or =15% and FN-related hospitalisation were also significantly lower with PPP. These data support PPP in breast cancer patients receiving chemotherapy with moderately high/high FN risk.
Authors	G von Minckwitz, M Schwenkglenks, T Skacel, G H Lyman, A Lopez Pousa, P Bacon, V Easton, M S Aapro
Journal	European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 45 Issue 4 Pg. 608-17 (Mar 2009) ISSN: 1879-0852 [Electronic] England
PMID	19110415 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
Chemical References	Recombinant Proteins Granulocyte Colony-Stimulating Factor pegfilgrastim Polyethylene Glycols Filgrastim
Topics	Adult Aged Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects) Breast Neoplasms (drug therapy) Drug Administration Schedule Female Fever (prevention & control) Filgrastim Granulocyte Colony-Stimulating Factor (therapeutic use) Humans Leukopenia (chemically induced, prevention & control) Male Middle Aged Neutropenia (chemically induced, prevention & control) Opportunistic Infections (prevention & control) Polyethylene Glycols Recombinant Proteins Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!